RVMD (RVMD) insider Goldsmith grants, exercises options and sells 36,000 shares

Rhea-AI Filing Summary

Revolution Medicines director and officer Mark A. Goldsmith reported option grants, share awards, option exercises and planned sales in RVMD stock. On March 1, 2026, he received stock options for 128,600 shares and 57,100 shares of common stock as grants, with the options vesting monthly over four years starting March 1, 2026.

On March 2, 2026, he exercised 30,000 stock options and acquired 30,000 common shares, then related accounts sold a total of 36,000 common shares in multiple open‑market trades around $98–$102 per share, including sales by family trusts under a Rule 10b5‑1 trading plan. After these transactions, he held 318,869 common shares directly plus additional shares indirectly through trusts, including 225,863 restricted stock units.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GOLDSMITH MARK A

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2026		A		57,100	A	$0	289,569(1)(2)	D
Common Stock	03/02/2026		M(3)		30,000	A	$4.09	319,569(1)	D
Common Stock	03/02/2026		S(3)		700	D	$98.1708(4)	318,869(1)	D
Common Stock	03/02/2026		S(3)		3,500	D	$99.7572(5)	315,369(1)	D
Common Stock	03/02/2026		S(3)		3,620	D	$100.7346(6)	311,749(1)	D
Common Stock	03/02/2026		S(3)		21,329	D	$101.6023(7)	290,420(1)	D
Common Stock	03/02/2026		S(3)		851	D	$102.1994(8)	289,569(1)	D
Common Stock								594,060(2)	I	Trust(9)
Common Stock	03/02/2026		S		100	D	$98.31	67,324	I	Trust(10)
Common Stock	03/02/2026		S		400	D	$100.1225(11)	66,924	I	Trust(10)
Common Stock	03/02/2026		S		1,700	D	$101.4743(12)	65,224	I	Trust(10)
Common Stock	03/02/2026		S		800	D	$101.9983(13)	64,424	I	Trust(10)
Common Stock	03/02/2026		S		100	D	$98.29	67,324	I	Trust(14)
Common Stock	03/02/2026		S		600	D	$100.1933(15)	66,724	I	Trust(14)
Common Stock	03/02/2026		S		2,100	D	$101.6341(16)	64,624	I	Trust(14)
Common Stock	03/02/2026		S		200	D	$102.08	64,424	I	Trust(14)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$102.02	03/01/2026		A		128,600		(17)	02/28/2036	Common Stock	128,600	$0	128,600	D
Stock Option (Right to Buy)	$4.09	03/02/2026		M(1)			30,000	03/13/2023	03/12/2029	Common Stock	30,000	$0	47,708	D

Explanation of Responses:

1. Includes 225,863 restricted stock units.

2. Reflects the transfer of 24,010 shares to the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

3. Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024.

4. This transaction was executed in multiple trades at prices ranging from $97.83 to $98.38. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. This transaction was executed in multiple trades at prices ranging from $99.12 to $100.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

6. This transaction was executed in multiple trades at prices ranging from $100.14 to $101.13. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

7. This transaction was executed in multiple trades at prices ranging from $101.14 to $102.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

8. This transaction was executed in multiple trades at prices ranging from $102.14 to $102.32. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

9. Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

10. Held by Jonathan Goldsmith Revocable Trust.

11. This transaction was executed in multiple trades at prices ranging from $99.79 to $100.71. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

12. This transaction was executed in multiple trades at prices ranging from $100.81 to $101.79. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

13. This transaction was executed in multiple trades at prices ranging from $101.82 to $102.14. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

14. Held by Rebecca Goldsmith Revocable Trust.

15. This transaction was executed in multiple trades at prices ranging from $99.80 to $100.71. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

16. This transaction was executed in multiple trades at prices ranging from $101.07 to $102.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

17. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Remarks:

President and Chief Executive Officer

	/s/ Jack Anders, as attorney-in fact for Mark A. Goldsmith	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did RVMD director Mark A. Goldsmith report?

Mark A. Goldsmith reported a mix of equity grants, option exercises, and open-market sales. He received option and stock awards, exercised 30,000 options, and related accounts sold 36,000 RVMD shares across several trades on March 2, 2026, at prices near $98–$102.

How many Revolution Medicines (RVMD) shares did Mark A. Goldsmith sell?

Entities associated with Mark A. Goldsmith sold a total of 36,000 RVMD common shares. These were executed in multiple open-market transactions, including sales by family trusts, at weighted average prices generally between about $98 and $102 per share on March 2, 2026.

What new RVMD equity awards did Mark A. Goldsmith receive?

Goldsmith received stock options for 128,600 RVMD shares and 57,100 shares of common stock as equity awards on March 1, 2026. The option grant vests in equal monthly installments over four years, contingent on his continued service through each vesting date.

How do trusts factor into Mark A. Goldsmith’s RVMD holdings?

Some RVMD shares are held by family trusts, including the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust and other revocable trusts. Several reported open-market sales on March 2, 2026, were executed by these trusts, reflecting indirect ownership interests associated with Goldsmith.

Were Mark A. Goldsmith’s RVMD stock sales under a 10b5-1 plan?

Yes. A footnote states that at least one set of transactions was made under a Rule 10b5‑1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. Such plans pre-schedule trades, providing a structured framework for insider stock sales over time.

How many RVMD shares does Mark A. Goldsmith hold after these transactions?

After the reported activity, Goldsmith held 318,869 RVMD common shares directly, plus additional shares indirectly through trusts. His direct holdings also include 225,863 restricted stock units, which represent share-based awards that typically convert into common stock as vesting conditions are met.